Compare · GILD vs LONA
GILD vs LONA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and LeonaBio Inc. (LONA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and LONA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 3915.1x LONA ($49.8M).
- Over the past year, GILD is up 24.9% and LONA is up 35.3% - LONA leads by 10.5 points.
- GILD has hit the wire 6 times in the past 4 weeks while LONA has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 4 for LONA).
- Company
- Gilead Sciences Inc.
- LeonaBio Inc.
- Price
- $153.79-1.56%
- $5.04-4.28%
- Market cap
- $195.13B
- $49.8M
- 1M return
- +2.52%
- -26.82%
- 1Y return
- +24.89%
- +35.35%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 4
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Latest LONA
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Portman David J.
- LeonaBio to Participate in Cantor Global Healthcare Conference 2026
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.
- LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
- LeonaBio upgraded by Citizens with a new price target
- SEC Form 4 filed by Director Perceptive Advisors Llc
- SEC Form 4 filed by Director Perceptive Advisors Llc
- SEC Form 4 filed by Director Callori Fred